Author Interviews, Brigham & Women's - Harvard, Genetic Research, JAMA, Karolinski Institute, Prostate Cancer / 05.07.2024
Prostate Cancer: Men With Genetic Risk at Increased Risk of Dying Early
MedicalResearch.com Interview with:
[caption id="attachment_62249" align="alignleft" width="204"]
Dr. Plym[/caption]
Anna Plym PhD
Department of Medical Epidemiology and Biostatistics,
Karolinska Institutet, Stockholm, Sweden
Department of Epidemiology, Harvard T. H. Chan School of Public Health
Department of Urology, Brigham and Women’s Hospital
Harvard Medical School, Boston, Massachusetts
MedicalResearch.com: What is the background for this study?
Response: Prostate cancer is one of the leading causes of cancer death among men, with approximately one third of the deaths occurring before the age of 75 years. There is a need for a better understanding of the risk factors for those early deaths. Our previous research has indicated that inherited factors play a major role.
Dr. Plym[/caption]
Anna Plym PhD
Department of Medical Epidemiology and Biostatistics,
Karolinska Institutet, Stockholm, Sweden
Department of Epidemiology, Harvard T. H. Chan School of Public Health
Department of Urology, Brigham and Women’s Hospital
Harvard Medical School, Boston, Massachusetts
MedicalResearch.com: What is the background for this study?
Response: Prostate cancer is one of the leading causes of cancer death among men, with approximately one third of the deaths occurring before the age of 75 years. There is a need for a better understanding of the risk factors for those early deaths. Our previous research has indicated that inherited factors play a major role.

Dr. Jernigan[/caption]
Dr. John Jernigan, MD MS
Clinical Associate Professor of Medicine
Division of Infectious Diseases
Emory University School of Medicine
Branch Chief
Epidemiology, Research and Innovations Branch
CDC Center for Disease Control
MedicalResearch.com: What is the background for this study?
Response: Staphylococcus aureus commonly causes infections in ICUs. One approach to preventing these infections is using nasal mupirocin plus chlorhexidine gluconate (CHG) bathing for ICU patients. This practice is known to prevent methicillin-resistant Staphylococcus aureus (MRSA) infections and all-cause. bloodstream infections. This practice has been broadly adopted in ICUs in the US, but adoption of mupirocin as a universal topical antibiotic has been slowed by concerns for engendering mupirocin resistance.
This cluster-randomized trial in adult ICUs was conducted to assess whether universal nasal antiseptic povidone-iodine (iodophor), to which minimal S. aureus resistance is expected, was an acceptable alternative to universal nasal mupirocin for reducing S. aureus and MRSA clinical cultures in the setting of daily CHG bathing. Those who received chlorhexidine (CHG) bathing with mupirocin had an 18% reduction in risk of Staphylococcus aureus clinical cultures and a 15% reduction in risk of methicillin-resistant
Dr. Caraballo-Cordovez[/caption]
César Caraballo-Cordovez, MD
